Figure 3.

DRFS stratified by 3 groups, pCR, RD/TP53 wt sig, and RD/TP53 mt sig. Patients were classified into 3 groups: pCR, RD and TP53 wild-type signature (RD/TP53 wt sig), and RD and TP53 mutant signature (RD/TP53 mt sig), after which DRFS was estimated in all patients (A), those with ER-positive subtype (B), and those with TNBC subtype (C). DRFS indicates distant recurrence-free survival; pCR, pathological complete response; RD, residual disease; TNBC, triple-negative breast cancer; TP53 mt sig, TP53 mutant signature; TP53 wt sig, TP53 wild-type signature.

*P < .05; ***P < .001.